Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

AstraZeneca

Status: Completed

Conditions: Coronary Heart Disease; Hyperlipidemias; Peripheral Vascular Diseases; Carotid Stenosis; Diabetes Mellitus; Atherosclerosis

Study type: Observational

Funder types: Industry

Identifiers

NCT00536796

NIS-CAT-CRE-2007/2

Details and patient eligibility

About

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Enrollment: 1,096 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion criteria

• Patients who do not receive cholesterol-lowering therapy

Trial design

1,096 participants in 4 patient groups

Patients at very high risk

Patients at high risk

Patients at medium risk

Patients at low risk